SUMO2 anticorps

N° du produit ABIN6940603

Détail du produit anti-SUMO2 anticorps

Antigène: SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))

Reactivité: Humain, Rat

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp SUMO2 est non-conjugé

Application: Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS), Staining Methods (StM)

Réactivité croisée (Details): Predicted to show a broad species reactivity.

Purification: Purified by Protein A/G

Immunogène: Recombinant human SUMO2 protein

Clone: SUMO2-1199

Isotype: IgG1 kappa

Information d'application

Indications d'application:

Positive Control: HeLa cells. Breast carcinoma.

Known Application: Flow Cytometry (0.5-1 μg/million cells), Immunofluorescence (0.5-1 μg/mL), Immunohistochemistry (Formalin-fixed) (0.5-1 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Stockage

Concentration: 200 μg/mL

Buffer: 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-80 °C

Stockage commentaire: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Date de péremption: 24 months

Détails sur SUMO2

Antigène: SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))

Autre désignation: SUMO2 (SUMO2 Produits)

Synonymes: anticorps HSMT3, anticorps SMT3B, anticorps SMT3H2, anticorps SUMO3, anticorps Smt3A, anticorps SMT3A, anticorps SMT3H1, anticorps SUMO-3, anticorps Smt3B, anticorps Smt3h2, anticorps sumo2, anticorps zgc:92241, anticorps SUMO2, anticorps SUMO-2, anticorps Smt3b, anticorps hsmt3, anticorps smt3b, anticorps smt3h2, anticorps sumo-2, anticorps PSMT3, anticorps ATSUMO2, anticorps MCO15.11, anticorps MCO15_11, anticorps SMALL UBIQUITIN-LIKE MODIFIER 2, anticorps SUM2, anticorps SUMO 2, anticorps small ubiquitin-like modifier 2, anticorps small ubiquitin-like modifier 2, anticorps small ubiquitin-like modifier 3, anticorps small ubiquitin-like modifier 2b, anticorps small ubiquitin-related modifier 2, anticorps small ubiquitin-like modifier 2 S homeolog, anticorps small ubiquitin-like modifier 2 L homeolog, anticorps SUMO2, anticorps SUMO3, anticorps Sumo2, anticorps sumo2b, anticorps LOC714892, anticorps sumo2.S, anticorps sumo2.L

Sujet: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.

Poids moléculaire: 11-13kDa

ID gène: 6613

UniProt: P55854

Pathways: Methionine Biosynthetic Process